Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma By Ogkologos - August 27, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMBI-I study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Breast Cancer May Spread by Recruiting Nearby Sensory Nerves September 20, 2024 Teacher Reads To Students One Day After Having Brain Surgery October 26, 2021 Cancer Research UK reports record levels of investment in its spinouts August 24, 2021 Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases June 20, 2023 Load more HOT NEWS When Natural Disasters Strike, This Program Helps Provide Relief To People... Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical...
